A new cure model that corrects for increased risk of non-cancer death: analysis of reliability and robustness, and application to real-life data

被引:7
|
作者
Botta, Laura [1 ,2 ,3 ]
Goungounga, Juste [2 ,3 ,4 ]
Capocaccia, Riccardo [5 ]
Romain, Gaelle [2 ,3 ]
Colonna, Marc [6 ,7 ]
Gatta, Gemma [1 ]
Boussari, Olayide [3 ,8 ]
Jooste, Valerie [2 ,3 ,7 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Epidemiol & Data Sci, Evaluat Epidemiol Unit, Via Venezian 1, I-20133 Milan, Italy
[2] Dijon Bourgogne Univ Hosp, Registre Bourguignon Canc Digest, F-21000 Dijon, France
[3] Univ Bourgogne Franche Comte, EPICAD team, UMR 1231, INSERM, Dijon, France
[4] Univ Rennes, EHESP, CNRS, Inserm,Arenes UMR 6051,RSMS U 1309, F-3500 Rennes, France
[5] Editorial Board, Epidemiol & Prevenz, Milan, Italy
[6] Ctr Hosp Univ Grenoble Alpes, Isere Canc Registry, F-38043 Grenoble 9, France
[7] FRANCIM, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France
[8] Federat Francophone Cancerol Digest FFCD, Dept Methodol, F-21000 Dijon, France
关键词
Cure model; Increased non-cancer mortality; Population-based data; Robustness; Reliability; Life tables; Net survival; Cancer; NET SURVIVAL; RELATIVE SURVIVAL; CANCER; PROPORTION; COLON;
D O I
10.1186/s12874-023-01876-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundNon-cancer mortality in cancer patients may be higher than overall mortality in the general population due to a combination of factors, such as long-term adverse effects of treatments, and genetic, environmental or lifestyle-related factors. If so, conventional indicators may underestimate net survival and cure fraction. Our aim was to propose and evaluate a mixture cure survival model that takes into account the increased risk of non-cancer death for cancer patients.MethodsWe assessed the performance of a corrected mixture cure survival model derived from a conventional mixture cure model to estimate the cure fraction, the survival of uncured patients, and the increased risk of non-cancer death in two settings of net survival estimation, grouped life-table data and individual patients' data. We measured the model's performance in terms of bias, standard deviation of the estimates and coverage rate, using an extensive simulation study. This study included reliability assessments through violation of some of the model's assumptions. We also applied the models to colon cancer data from the FRANCIM network.ResultsWhen the assumptions were satisfied, the corrected cure model provided unbiased estimates of parameters expressing the increased risk of non-cancer death, the cure fraction, and net survival in uncured patients. No major difference was found when the model was applied to individual or grouped data. The absolute bias was < 1% for all parameters, while coverage ranged from 89 to 97%. When some of the assumptions were violated, parameter estimates appeared more robust when obtained from grouped than from individual data. As expected, the uncorrected cure model performed poorly and underestimated net survival and cure fractions in the simulation study. When applied to colon cancer real-life data, cure fractions estimated using the proposed model were higher than those in the conventional model, e.g. 5% higher in males at age 60 (57% vs. 52%).ConclusionsThe present analysis supports the use of the corrected mixture cure model, with the inclusion of increased risk of non-cancer death for cancer patients to provide better estimates of indicators based on cancer survival. These are important to public health decision-making; they improve patients' awareness and facilitate their return to normal life.
引用
收藏
页数:19
相关论文
共 12 条
  • [1] A new cure model that corrects for increased risk of non-cancer death: analysis of reliability and robustness, and application to real-life data
    Laura Botta
    Juste Goungounga
    Riccardo Capocaccia
    Gaelle Romain
    Marc Colonna
    Gemma Gatta
    Olayidé Boussari
    Valérie Jooste
    BMC Medical Research Methodology, 23
  • [2] Analysis of novel fractional COVID-19 model with real-life data application
    Inc, Mustafa
    Acay, Bahar
    Berhe, Hailay Weldegiorgis
    Yusuf, Abdullahi
    Khan, Amir
    Yao, Shao-Wen
    RESULTS IN PHYSICS, 2021, 23
  • [3] Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data
    Dudnik, Elizabeth
    Goldstein, Daniel
    Roisman, Laila
    Hammerman, Ariel
    Greenberg-Dotan, Sari
    Bar, Jair
    Moskovitz, Mor
    Daher, Sameh
    Shamai, Sivan
    Hanovich, Ekaterina
    Shechtman, Yelena
    Abu-Amna, Mahmoud
    Zer, Alona
    Wollner, Mira
    Merimsky, Ofer
    Cyjon, Arnold
    Peled, Nir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1432 - S1433
  • [4] A new non-parametric hypothesis testing with reliability analysis applications to model some real data
    Bakr, M. E.
    Kibria, B. M. Golam
    Gadallah, A. M.
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2023, 16 (04)
  • [5] Wearable cardioverter defibrillator after cardiac surgery: Analysis of real-life data from patients at transient risk of sudden cardiac death
    Elbayomi, Mohamed
    Weyand, Michael
    Seitz, Timo
    Harig, Frank
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2023, 28 (02)
  • [6] Nivolumab treatment in advanced non-small cell lung cancer (NSCLC): Retrospective analysis of real-life data in the Hospital Universitario Reina Sofia (HURS).
    GarcAa DurAin, Carmen
    Moreno-Vega, Alberto L.
    Sanchez Maurino, Pedro
    Lopez-Gonzalez, Javier
    Barneto-Aranda, Isidoro C.
    De La Haba, Juan
    Aranda Aguilar, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [7] LONG-TERM ANALYSIS OF ACTIVE SURVEILLANCE PROTOCOLS IN LOW-RISK PROSTATE CANCER: REAL-LIFE DATA MAY CHANGE FOLLOW-UP SCHEDULES
    Casbarra, Alessia
    Avuzzi, Barbara
    Badenchini, Fabio
    Catanzaro, Mario
    Macchi, Alberto
    Nazzani, Sebastiano
    Chiorda, Barbara Noris
    Stagni, Silvia
    Tesone, Antonio
    Villa, Sergio
    Marenghi, Cristina
    Nicolai, Nicola
    ANTICANCER RESEARCH, 2023, 43 (10) : 4766 - 4767
  • [8] Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
    Gutierrez, Lourdes
    Royuela, Ana
    Carcereny, Enric
    Lopez-Castro, Rafael
    Rodriguez-Abreu, Delvys
    Massuti, Bartomeu
    Luis Gonzalez-Larriba, Jose
    Garcia-Campelo, Rosario
    Bosch-Barrera, Joaquim
    Guirado, Maria
    Camps, Carlos
    Domine, Manuel
    Bernabe, Reyes
    Casal, Joaquin
    Oramas, Juana
    Laura Ortega, Ana
    Angeles Sala, Ma
    Padilla, Airam
    Aguiar, David
    Juan-Vidal, Oscar
    Blanco, Remei
    del Barco, Edel
    Martinez-Banaclocha, Natividad
    Benitez, Gretel
    de Vega, Blanca
    Hernandez, Ainhoa
    Saigi, Maria
    Franco, Fernando
    Provencio, Mariano
    BMC CANCER, 2021, 21 (01)
  • [9] Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
    Lourdes Gutiérrez
    Ana Royuela
    Enric Carcereny
    Rafael López-Castro
    Delvys Rodríguez-Abreu
    Bartomeu Massuti
    José Luis González-Larriba
    Rosario García-Campelo
    Joaquim Bosch-Barrera
    María Guirado
    Carlos Camps
    Manuel Dómine
    Reyes Bernabé
    Joaquín Casal
    Juana Oramas
    Ana Laura Ortega
    Mª. Angeles Sala
    Airam Padilla
    David Aguiar
    Oscar Juan-Vidal
    Remei Blanco
    Edel del Barco
    Natividad Martínez-Banaclocha
    Gretel Benítez
    Blanca de Vega
    Ainhoa Hernández
    Maria Saigi
    Fernando Franco
    Mariano Provencio
    BMC Cancer, 21
  • [10] Covid 19 infection leading to a subsequent new primary cancer diagnosis, Real-world data (RWD) analysis on members of Belong.life, a global cancer application (app).
    Vorobiof, Daniel A.
    Haikin, Bozhena
    Litvin, Alon
    Deutsch, Irad
    Malki, Eliran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18775 - E18775